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Arsenic is a potent human carcinogen. Around one hundred million people worldwide have potentially been exposed to this
metalloid at concentrations considered unsafe. Exposure occurs generally through drinking water from natural geological sources,
making it diﬃcult to control this contamination. Arsenic biotransformation is suspected to have a role in arsenic-related health
eﬀects ranging from acute toxicities to development of malignancies associated with chronic exposure. It has been demonstrated
that arsenic exhibits preference for induction of squamous cell carcinomas in the human, especially skin and lung cancer.
Interestingly, keratins emerge as a relevant factor in this arsenic-related squamous cell-type preference. Additionally, both genomic
and epigenomic alterations have been associated with arsenic-driven neoplastic process. Some of these aberrations, as well as
changes in other factors such as keratins, could explain the association between arsenic and squamous cell carcinomas in humans.
1.Background
Arsenic is a well-known human carcinogen (Class I, accord-
ing to the International Agency for Research on Cancer—
IARC [1]). Recommended thresholds for arsenic concentra-
tion in drinking water is ≤10µg/L [2, 3] however, chronic
exposure exceeding this limit has been reported worldwide
aﬀecting nearly one hundred million people worldwide
daily, especially in Bangladesh, Taiwan, Mongolia, India,
China, Argentina, Mexico, Canada, USA, and Chile, among
others countries [4–9]. Long-term eﬀects are a major health
concern in aﬀected areas.
In the environment, arsenic can be found with an
oxidation state +3 (known as arsenite or As [III]), or +5
(arsenate or As [V]), exhibiting diﬀerent grades of toxicity
[10]. Increased levels of inorganic arsenic (combined with
oxygen, chlorine, and sulfur, among other elements) in
drinking water is the major cause of arsenic toxicity [11, 12].
Both neoplastic and nonneoplastic eﬀects have been
describedasconsequenceofarsenicexposure.Nonneoplastic
eﬀects primarily include peripheral vascular disorders (e.g.,
“black foot disease” almost exclusively observed in zones
of Taiwan aﬀected by arsenic contamination [13]), hyper-
tension, diabetes, severe atherosclerosis, neuropathies, and,
importantly, skin alterations, such as hyperkeratosis and
hyperpigmentation [13–16]. Hyperkeratosis is particularly
relevant, because it has been described as a precursor lesion
of skin cancer tumors associated with arsenic exposure [17–
19].
Several types of cancer have been attributed to arsenic
exposure [20–25]. Skin, bladder, and lungs are the major
target organs aﬀected by diﬀerent routes of exposure. Skin
cancer is the most common form of malignant tumor related
to arsenic ingestion. Lung cancer is the most deadly form of
cancer associated to arsenic exposure [26, 27]. For internal
organs, bladder cancer exhibits the highest relative risk [20,
28, 29]. Other less common types of cancer associated with
arsenic exposure include kidney, liver, and prostate cancers
[30, 31].
The mechanism of arsenic-induced diseases remains to
be elucidated. When arsenic enters the human body, it is
readily reduced from the pentavalent arsenical species to
trivalent forms, and, subsequently, there are a series of
oxidative methylation reactions leading to the generation of
tri- and pentavalent methylated metabolites [32]. It has been
proposed that the biotransformation processes of arsenic
activate its carcinogenic potential. This hypothesis was
supported by the observation that the methylated arsenical2 Journal of Skin Cancer
species (specially trivalents) exhibit aberrant eﬀects such as
enzyme inhibition (particularly oxidoreductases), damage
to DNA structure, and activation AP-1-dependent gene
transcription [33, 34].
Neoplastic eﬀects as a result of arsenic biotransformation
can occur at the genetic and epigenetic levels. Arsenic can
damage DNA, mostly through oxidative stress by generation
of toxic species such as reactive oxygen species (ROS), which
can potentially lead to genomic aberrations.
Figure 1 Secondly, arsenic uses S-adenosylmethionine
(SAM) as a methyl group donor during its biotransforma-
tion. As a consequence, deprivation of the cellular pool of
methyl groups can block certain cellular processes, resulting
in alteration of epigenetic mechanisms that can contribute
to arsenic-induced carcinogenesis [35]. Arsenic and arsenic
metabolites can directly and indirectly aﬀect normal epi-
genetic transcriptional regulation at the level of DNA
methylation, histone maintenance, and miRNA expression
(Figure 1)[ 36, 37].
1.1. Cell-Type Speciﬁcity on Arsenic-Induced Cancers. Despite
physiological diﬀerences among target organs for arsenic
carcinogenicity,acommoncharacteristichasbeendescribed,
namely, a squamous cell-type preference, independent of the
aﬀected organ. In fact, SqCC is one of the most common
cancers seen in chronic-arsenic-exposed humans [38, 39].
Cell-type speciﬁcity has been previously described mainly
for skin and lung cancer, and some studies have shown
associations with liver cancer [40, 41]. In this paper, we will
focus on speciﬁcity reported in two main arsenic-associated
types of cancer, namely, skin and lung cancers.
1.2. Skin Cancer and Arsenic Exposure. Skin cancer is the
most common malignancy associated with arsenic ingestion
through drinking water [26]. There are three major patho-
logical cell types of skin cancer: basal cell carcinoma (BCC),
squamouscellcarcinoma(SqCC),andmalignantmelanoma.
The ﬁrst two cell types are the most common types of skin
cancer, and they belong to the group of nonmelanoma skin
cancers. Exposure to arsenic in drinking water has been
associatedwiththeincidenceofSqCCandBCC,butnotwith
the incidence of malignant melanoma [42]. Arsenic-related
SqCC of the skin can develop either de novo or progress
from Bowen’s disease (BD), a premalignant skin disorder,
frequently reported as a consequence of chronic arsenic
exposure[43–46].Additionally,therearediﬀerencesbetween
skin cancer cases induced and not induced by arsenic. For
example, arsenic-related BCC develops typically in non-sun-
exposed areas of the body (contrary to UV-related skin
cancer) and exhibits multiple foci [47].
Cell type speciﬁcity has been directly observed in chron-
ically exposed human populations. In a key study from Tai-
wan, SqCC and BCC appear to be associated with ingestion
of arsenic [42]. However, prior to skin cancer, the ﬁrst
observed eﬀects of chronic arsenic exposure were nonmalig-
nant skin lesions, such as hyperpigmentation and hyperker-
atosis [43, 48]. Skin hyperkeratosis is common in chronic
arsenicosis and is considered a precursor of SqCC because
cancer can arise from these lesions [17–19].
Arsenic tends to concentrate in ectodermal tissue includ-
ing the skin, hair, and nails [48]. Dermal absorption of
arsenic is not the main exposure route, since some derivates
of arsenic metabolism have low permeability [49, 50];
however, both arsenite and arsenate accumulate in the
dermis and epidermis [49]. In this context, epidermal stem
cells have been proposed as a potential target for arsenic-
induced carcinogenesis, since this metalloid can increase the
relative proportion of stem cells in culture [51, 52].
Keratinocyte stem cells (KSCs) are a group of relatively
quiescent cells with a broad proliferative potential and an
unlimited capacity for self-renewal [53, 54]. DSS1 (deleted in
split hand/split foot 1) is a 12-O-tetradecanoyl phorbol-13-
acetate-(TPA-) inducible gene expressed in KSCs that plays
an important role in skin carcinogenesis and is required for
epidermal cell proliferation and oncogenic transformation
[55]. DSS1 expression was signiﬁcantly increased in SqCC
induced in adult skin of Tg.AC mice—a strain sensitive to
skin carcinogenesis via activation of the v-Ha-ras transgene
likely in KSCs—by arsenic plus TPA compared with TPA
alone [56]. Other genes responding to the same activation
mechanisms in skin cancer, such Sprr2a, Ptges,a n dCol1a2,
were also increased in SqCC developed in Tg.AC mice
[56, 57]. Arsenic also has the potential to induce malig-
nant transformation of human keratinocytes. Immortalized
human epithelial cell line (HaCaT) exposed to 100nM of
arsenicover28weeksgeneratedhighlyaggressiveSqCCwhen
inoculated into nude mice [58].
Matrix metalloproteinase 9 (MMP-9) plays an important
role in tumor progression, speciﬁcally in metastatic capacity,
and its constitutive secretion correlates with the degree of
tumorigenicityinhumankeratinocytes[59,60].Humanker-
atinocytes transformed by arsenic exhibit an increased secre-
tion of MMP-9, to a similar degree observed in SqCC gen-
erated after inoculation of arsenic-transformed cells in mice
[58]. This indicates that an aberrant expression of MMP-9
could be an early marker for arsenic-induced skin SqCC.
Finally, it has been suggested that arsenic can act as a
skin cocarcinogen (Figure 1). In this context, it has been
demonstratedthatlowconcentrationsofarseniccanincrease
tumorinductionbyUV-lightinmice,withahighproportion
of SqCC [61].
1.3. Lung Cancer and Arsenic Exposure. Lung cancer is the
most deadly form of cancer associated to arsenic ingestion
[27]. Several reports have shown a higher incidence of
lung SqCC in populations exposed to arsenic (Table 1).
This relationship has been demonstrated in several human
populations. In Taiwan, patients from an endemic area of
arsenic intoxication with exposures through drinking water
had higher proportions of squamous cell and small cell car-
cinomas, but a lower proportion of adenocarcinomas [40].
In northern Chile, a high proportion of SqCC frequently
occurs in never smokers who have been chronically exposed
to arsenic, which is interesting, since SqCC is very frequently
associated with cigarette smoking and its incidence has
decreased worldwide [24, 62]. In rural areas of Bangladesh,
arsenic contamination in drinking water from tube wells is
associated with lung cancer in males, with lung SqCC beingJournal of Skin Cancer 3
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Figure 1: Carcinogenic mechanisms of arsenic transformation. Ingested arsenic undergoes a biotransformation process. (1) Biotransforma-
tion could lead to arsenic excretion, when conjugated with glutathione. (2) Biotransformation generates reactive oxygen species (ROS),
namely, superoxide anions (O2
−), hydrogen peroxide (H2O2), hydroxyl radicals (OH), that induce single-strand (ssDNA) and double-
strand (dsDNA) breaks by inducing oxidative damage. The process can also inhibit DNA break repair mechanisms for ssDNA breaks (base
excisionrepair(BER))andfordsDNAbreaks(homologousrecombination(HR)and/ornonhomologousendjoining(NHEJ)).Additionally,
ROS derived from arsenic biotransformation can act as cocarcinogens, for example, increasing damage potential of ultraviolet (UV) light.
Furthermore, the requirement of S-adenosyl methionine (SAM) for arsenic biotransformation can lead to depletion of SAM, which is the
substrate for DNA methylation.
the predominant histological subtype in areas with arsenic
concentrations above 100µg/L [63]. Additionally, lung SqCC
was much more frequent among Bangladesh inhabitants
who smoke and are exposed to arsenic in drinking water
(concentrations >100mg/L) compared to nonsmokers [63].
Studies in people occupationally exposed to arsenic have
also revealed cell type speciﬁcity for arsenic-induced lung
cancer. A postmortem study found that 37.6% of lung cancers
among wine growers aﬀected by chronic arsenic poisoning
were of the SqCC type, a proportion signiﬁcantly higher
compared with three of the four reference populations [64].
On the other hand, smelter workers exposed to arsenic did
not exhibit major changes in histological distribution for
lung cancer (compared with reference group); however, lung
SqCC has the highest number of cases, even among never
smokers [65, 66]. Conversely, other studies have shown no
diﬀerences in histological types of lung cancer associated
with arsenic exposure, challenging the hypothesis that small
cell undiﬀerentiated and epidermoid (SqCC) carcinomas are
the only subtypes that increase in response to arsenic, among
other carcinogens [67].
Information from German uranium miners who died
from lung cancer during 1957–1990 was analyzed under the
hypothesisthatarsenicmayinﬂuencethedistributionoflung
cancer types [68]. There was an arsenic-related increase in
the proportion of lung SqCC among miners without silicosis
at all levels of coexposure to radon and quartz dust.
1.4. Role of Keratins in Arsenic-Induced SqCC. The main
structural proteins of the intermediate ﬁlament-based
cytoskeleton of epithelial cells are the keratins [69]. Keratins
are closely related with tissue-speciﬁc and cell-speciﬁc dif-
ferentiation of epithelial cells [70], accordingly their roles
in arsenic-induced SqCC have been explored. Interestingly,
arsenic-inducedcarcinogenesisisrelatedtoenhancedexpres-
sion of these cytoskeletal proteins in skin, liver, and bladder
[41, 58, 71–73].
Hyperkeratinization of stratiﬁed epithelia is a common
clinical manifestation of arsenic exposure [17]. Notably,
arsenic-associated SqCC typically arises from arsenic-
inducedhyperkeratoticlesions,suggestingthatdysfunctional
keratinization may play a critical role in arsenic-induced car-
cinogenesis [18]. In human keratinocytes, arsenic has been
shown to promote a dramatic increase in expression of CK1,
CK10,involucrin,andloricrin[58],whicharemajormarkers
of squamous diﬀerentiation [74]. The epidermal stem cell
markers CK5, CK14, and CK15 have also been shown to
increase with arsenic exposure [72, 75–77]. CK8, CK17, and
CK18 which are overexpressed in invasive SqCC, are also
induced in arsenic-treated keratinocytes [72]. In addition
to cell model studies, a population-based report of chronic
arsenic exposure in Taiwan revealed progressive alterations
in keratin expression in various skin lesions, including
hyperkeratosis and SqCC. In this study, CK6, CK16, and
CK17 were associated with arsenic exposure in SqCC [73].
The disruption in keratins induced by arsenic pro-
motes the formation of DNA-protein cross-links, which
can impair DNA replication [41]. The fact that arsenic has
ah i g ha ﬃnity to thiol groups, including those attached
to thiol-rich proteins such as keratins, might contribute4 Journal of Skin Cancer
Table 1: Studies exhibiting associations between arsenic exposition and cell types of lung cancer.
Location Number of lung
cancer cases Cell type Smoking status Calculated risk Dosage Reference
Britain
6 cases treated
with Fowler’s
solution or
potassium
arsenite (2 male/4
female)
(i) 5
undiﬀerentiated
carcinomas
(ii) 1 SqCC
3 never smokers,
1s m o k e r NA NA [94]
Taiwan
(i) 76 LC cases
(50 males/36
females)
(ii) 400 controls
from the same
administrative
area
(i) Male cases: 40%
SqCC, 38% AdC,
22% others
(ii) Female cases:
19% SqCC, 69%
AdC, 11% others
NA
Odds ratios for developing LC
were 3.39 for whom used well
water from arsenic-contaminated
zones during 40 or more years,
compared with people who never
used such water source
Median of
780µg/L (artesian
wells) and 40µg/L
(in well water)
[95]
Japan: Niigata
Prefecture
(i) 443
individuals
exposed to
arsenic
(ii) 9 (8
male/1female)
developed lung
cancer after
exposure to high
levels
(≥1000µg/L)
(i) 3 SCC
(ii) 2 SqCC
(iii) 1 SqCC + SCC
All smokers,
except for female
case
SMR = 15.6 for developing LC
among individuals (N = 113)
exposed to >1000µg/L of arsenic
in drinking water in a zone
contaminated during 5 years in
Japan, while individuals exposed
to 50−990µg/L (N = 76) present a
SMR of 2.33
[96]
Southwest
and
northeast
Taiwan
139 newly
diagnosed LC
cases from a BFD
endemic zone
(i) 45% SqCC
(ii) 22% AdC
(i) 31.9% never
smokers
(ii) 16.7% past
smokers
(iii) 51.4%
current smokers
Relative risk according to exposure
group
(i) Group 1: 1
(ii) Group 2: 1.09
(iii) Group 3: 2.28
(iv) Group 4: 3.03
(v) Group 5: 3.29
Average arsenic
level in
groundwater
(µg/L)
(i) Group 1: <10
(ii) Group 2:
10–99l
(iii) Group 3:
100–299l
(iv) Group 4:
300–699
(v) Group
5: ≥700
[97]
Taiwan
National Cancer
Registration
Program with
37.290 LC
patients (26.850
men/10.440
women
Men†
(i) 33.6% SqCC
(ii) 19.5% AdC
Women†
(i) 29.9% SqCC
(ii) 29.6% SqCC
NA
Male and female patients from
the BFD area had higher
proportions of SqCC
(RR = 1.1i nm e na n dR R= 1.9
in women) and SCC (RR = 1.2,
in men, and RR = 2.3, in
women) but had a lower
proportion of AdC
(RR = 0.7i nm e na n d
RR = 0.6i nw o m e n )
(i) Towns in BFD
area: average
arsenic level of
0.22mg/L in well
water
(ii) Control
towns:
average arsenic
level of 0.02mg/L
[40]
Bangladesh
(i) 3.223 (2811
male) with
ap r i m a r yL C
(ii) 1588 (1183
male) with
benign lesions
50.5% and 39.0%
of SqCC among
smokers and
nonsmokers,
respectively
(i) 79.7%
smokers
(ii) 18.5% never
(iii) 1.80%
unknown
OR = 1.45,
(95% CI 1.16−1.80) >100µg/L [63]Journal of Skin Cancer 5
Table 1: Continued.
Location Number of lung
cancer cases Cell type Smoking status Calculated risk Dosage Reference
Northeastern
Taiwan
(i) 8086 residents
were followed for
11 years (6888
remained in the
ﬁnal analysis)
(ii) 178 incident
LC cases
(i) 75 (42.1%)
SqCC
(ii) 51 (28.7%)
AdC
(iii) 22 (12.4%)
SCC
At enrollment
(i) 59.0% never
smokers
(ii) 12.4% past
(iii) 28.6%
current
The RRs and 95% CIs for 100–300
and >300µg arsenic/L when
compared with <10µg arsenic/L
were 1.54 (0.97–2.46) and 2.25
(1.43–3.55), respectively
The mean
(arsenic) among
wells with known
arsenic
concentration
was 117.2µg/L
[98]
USA: New
Hampshire,
Vermont.
(i) 223 lung
cancer (100
male/123 female)
(ii) 238 controls
75 cases were SqCC
and SCC
Data from cases
(i) 5.4% never
smokers
(ii) 94.6% current
Arsenic exposure was associated
with SCC and SqCC (OR = 2.75
for toenail arsenic concentration
≥0.114µg/g versus <0.05µg/g)
Toe nail (arsenic)
in 4 levels:
<0.05µg/g, 0.05
to <0.0768µg/g,
0.768
to <0.1137µg/g,
and ≥0.1137µg/g
[99]
†Data from patients from the Blackfoot Disease area in Taiwan.
SCC: small cell carcinoma; NA: data not available; SMR: standardized mortality rate; OR: odds ratios.
to its accumulation in epithelial tissues leading to further
DNA-protein cross-links, DNA damage, and possibly other
defects. Indeed, keratin synthesis is tightly correlated with
diﬀerentiation programs of a range of epithelial cell types
[78].Therefore,arseniccouldnotonlydamageDNAbutalso
modify diﬀerentiation patterns in the cells where it accumu-
lates. The subsequent arsenic-induced genetic and epigenetic
alterations could ﬁnally lead to the development of SqCC.
1.5. Genetic and Epigenetic Alterations Associated with Arsenic
Exposure. Some genetic alterations have been described to
be speciﬁcally associated to arsenic ingestion in humans.
For example, Moore et al. identiﬁed genomic changes in
bladder tumors (transitional cell carcinoma, TCC) from
arsenic-exposed patients using chromosomal comparative
genomic hybridization (CGH) [79]. Among diﬀerent recur-
rent arsenic-related DNA copy number alterations (CNAs)
identiﬁed, DNA loss of chromosome 9q is remarkable, since
it was the only alteration more frequently observed in never
smokers than in ever smokers in this study. Similarly, Hsu et
al. identiﬁed CNAs on bladder TCC tumors from southwest
Taiwan [80]. Gain at 3p and loss at 17p13 were consistent
with ﬁndings from northern Chile and Argentina.
Recently, arsenic-related CNAs were identiﬁed among
lungSqCCsfromchronicallyexposedpatientsfromnorthern
Chile [81]. Alterations were identiﬁed by a whole genome
tiling-path array comparative genomic hybridization (CGH)
platform (described in [82, 83]). Noticeably, a 0.3 Mb DNA
loss at 9q12 was preferentially detected among arsenic-
exposed cases (Figure 2). The role of chromosome 9q
on arsenic-induced human tumors needs to be further
investigated; however, common alterations detected among
bladder and lung tumors indicate a potential participation
on arsenic-related neoplastic process.
Arsenic also has epigenetic eﬀects at the level of DNA
methylation, histone maintenance, and miRNA expression
(reviewed in [36, 37, 84]). Since arsenic biotransformation
uses S-adenosylmethionine (SAM) as a methyl group donor,
it has been proposed that SAM depletion can interfere with
cellular processes that require methyl groups, leading to
the idea that alteration of epigenetic mechanisms can also
participate in arsenic-induced carcinogenesis [35]. Promoter
hypermethylation aﬀecting P53, p16INK4A, RASSF1A, and
PRSS3 has been described in lung cancer cell lines and
tumor tissues from mice and human [85–87]. On the
other hand, arsenic can modify normal histone patterns. As
[III] has also been shown to increase H3K9 dimethylation
and decrease H3K27 trimethylation, marks associated with
heterochromatin formation (i.e., gene silencing) and a
decrease in H3K4 trimethylation which is associated with
actively transcribed euchromatin [88]. In human nontumor-
ogenic cell lines, arsenic-induced malignant transformation
provoked changes in expression for speciﬁc genes, which
was correlated with the histone acetylation levels for their
respective promoter regions [89].
In the few past years, miRNAs have been intensively
studiedinthecontextofarsenic-relatedcancer.Anincreasing
number of studies show that arsenic exposure can alter
miRNA expression levels in vitro and in vivo.m i R N A
alterations associated with arsenic (or its metabolites) have
been demonstrated in human lymphoblastoid cells, human
peripheral blood-derived cells, and chick embryos [87, 90].
Exposure of immortalized human bronchial epithelial cells
to low levels of arsenic induced malignant transformation
and epithelial-to-mesenchymal transition in p53- dependent
manner by reducing levels of miR-200 family members [91].
In the case of human peripheral blood-derived cells, changes
in miRNA could be related with changes in methylation
patterns, since the same alterations were observed when cells
weregrownunderfolate-deﬁcientconditions,whichcanlead
to reduced levels of SAM [87].
2. Conclusion
Arsenic in drinking water aﬀects millions of people world-
wide, posing an urgent health concern [92]. Hundreds of6 Journal of Skin Cancer
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Figure 2: DNA copy-number alteration at chromosome 9q in
arsenic-exposed lung SqCC. CNA frequencies are overlaid in this
karyogram. Proﬁles of 52 lung SqCC biopsies were generated using
a submegabase resolution tiling-set rearray (SMRTr) platform.
Twenty-two arsenic-exposed samples (shown in red) were obtained
from lung cancer patients from northern Chile. Thirty samples
from patients without known arsenic exposure (green) were
obtained from North American individuals. Regions in yellow
denote a sector of overlapping alteration status in both groups.
The magnitude of red, green, and yellow bars represents percentage
of samples (0–100%, with blue vertical lines representing 50%
frequency) exhibiting DNA gains (to the right) and DNA losses (to
the left). Dotted line represents 9q12 cytoband.
millions of people have been exposed to this metalloid
throughdrinkingwater,resultinginmorbidityandmortality
globally [5, 6]. Arsenic causes a variety of health problems,
signiﬁcantly cancer, whose symptoms may not appear for 20
to 30 years after exposure [93].
Several genomic aberrations have been described for
arsenic-induced cancers. Based on distinctive proﬁles of
genomic changes, it has been proposed that arsenic-induced
lung SqCC could correspond to a molecularly distinct form
of lung cancer [81]. Additionally, the arsenic biotransfor-
mation process is associated with a series of methylation
changes, which has led to the hypothesis that epigenetic
changes play a key role in arsenic-induced carcinogenesis.
Changes in DNA methylation patterns (especially at pro-
moter regions of key genes) and alterations to the “histone
code” are likely mechanisms of arsenic-induced malignant
transformation. Additionally, miRNAs seem to play an
important role at this level.
Understanding the mechanisms underlying the prefer-
ential occurrence of squamous cell-type tumors associated
with arsenic exposure, especially skin and lung cancer, is
an urgent health care issue. Arsenic has been shown to
promote a dramatic increase in expression of keratins related
to squamous diﬀerentiation, which can be, in part, a con-
sequence of genetic and epigenetic changes associated with
arsenic biotransformation. This corresponds to a potential
mechanism for explaining the preferential histological sub-
type induced by arsenic, independent of the target organ.
Further research is needed in order to clarify the molecular
mechanisms governing arsenic-driven carcinogenesis, as well
as preference for histological subtypes. This knowledge can
improve strategies oriented to early diagnosis or targeted
therapies of these and other arsenic-related diseases.
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